187 related articles for article (PubMed ID: 31597710)
1. Applying the ATN scheme in a memory clinic population: The ABIDE project.
Altomare D; de Wilde A; Ossenkoppele R; Pelkmans W; Bouwman F; Groot C; van Maurik I; Zwan M; Yaqub M; Barkhof F; van Berckel BN; Teunissen CE; Frisoni GB; Scheltens P; van der Flier WM
Neurology; 2019 Oct; 93(17):e1635-e1646. PubMed ID: 31597710
[TBL] [Abstract][Full Text] [Related]
2. Cerebrovascular and amyloid pathology in predementia stages: the relationship with neurodegeneration and cognitive decline.
Bos I; Verhey FR; Ramakers IHGB; Jacobs HIL; Soininen H; Freund-Levi Y; Hampel H; Tsolaki M; Wallin ÅK; van Buchem MA; Oleksik A; Verbeek MM; Olde Rikkert M; van der Flier WM; Scheltens P; Aalten P; Visser PJ; Vos SJB
Alzheimers Res Ther; 2017 Dec; 9(1):101. PubMed ID: 29284531
[TBL] [Abstract][Full Text] [Related]
3. Discordant amyloid-β PET and CSF biomarkers and its clinical consequences.
de Wilde A; Reimand J; Teunissen CE; Zwan M; Windhorst AD; Boellaard R; van der Flier WM; Scheltens P; van Berckel BNM; Bouwman F; Ossenkoppele R
Alzheimers Res Ther; 2019 Sep; 11(1):78. PubMed ID: 31511058
[TBL] [Abstract][Full Text] [Related]
4. PET and CSF amyloid-β status are differently predicted by patient features: information from discordant cases.
Reimand J; de Wilde A; Teunissen CE; Zwan M; Windhorst AD; Boellaard R; Barkhof F; van der Flier WM; Scheltens P; van Berckel BNM; Ossenkoppele R; Bouwman F
Alzheimers Res Ther; 2019 Dec; 11(1):100. PubMed ID: 31810489
[TBL] [Abstract][Full Text] [Related]
5. ATN classification and clinical progression in subjective cognitive decline: The SCIENCe project.
Ebenau JL; Timmers T; Wesselman LMP; Verberk IMW; Verfaillie SCJ; Slot RER; van Harten AC; Teunissen CE; Barkhof F; van den Bosch KA; van Leeuwenstijn M; Tomassen J; Braber AD; Visser PJ; Prins ND; Sikkes SAM; Scheltens P; van Berckel BNM; van der Flier WM
Neurology; 2020 Jul; 95(1):e46-e58. PubMed ID: 32522798
[TBL] [Abstract][Full Text] [Related]
6. Associations of Amyloid, Tau, and Neurodegeneration Biomarker Profiles With Rates of Memory Decline Among Individuals Without Dementia.
Jack CR; Wiste HJ; Therneau TM; Weigand SD; Knopman DS; Mielke MM; Lowe VJ; Vemuri P; Machulda MM; Schwarz CG; Gunter JL; Senjem ML; Graff-Radford J; Jones DT; Roberts RO; Rocca WA; Petersen RC
JAMA; 2019 Jun; 321(23):2316-2325. PubMed ID: 31211344
[TBL] [Abstract][Full Text] [Related]
7. The implications of different approaches to define AT(N) in Alzheimer disease.
Mattsson-Carlgren N; Leuzy A; Janelidze S; Palmqvist S; Stomrud E; Strandberg O; Smith R; Hansson O
Neurology; 2020 May; 94(21):e2233-e2244. PubMed ID: 32398359
[TBL] [Abstract][Full Text] [Related]
8. Association of Amyloid Positron Emission Tomography With Changes in Diagnosis and Patient Treatment in an Unselected Memory Clinic Cohort: The ABIDE Project.
de Wilde A; van der Flier WM; Pelkmans W; Bouwman F; Verwer J; Groot C; van Buchem MM; Zwan M; Ossenkoppele R; Yaqub M; Kunneman M; Smets EMA; Barkhof F; Lammertsma AA; Stephens A; van Lier E; Biessels GJ; van Berckel BN; Scheltens P
JAMA Neurol; 2018 Sep; 75(9):1062-1070. PubMed ID: 29889941
[TBL] [Abstract][Full Text] [Related]
9. Injury markers but not amyloid markers are associated with rapid progression from mild cognitive impairment to dementia in Alzheimer's disease.
van Rossum IA; Visser PJ; Knol DL; van der Flier WM; Teunissen CE; Barkhof F; Blankenstein MA; Scheltens P
J Alzheimers Dis; 2012; 29(2):319-27. PubMed ID: 22233766
[TBL] [Abstract][Full Text] [Related]
10. Longitudinal change in ATN biomarkers in cognitively normal individuals.
Ebenau JL; Visser D; Kroeze LA; van Leeuwenstijn MSSA; van Harten AC; Windhorst AD; Golla SVS; Boellaard R; Scheltens P; Barkhof F; van Berckel BNM; van der Flier WM
Alzheimers Res Ther; 2022 Sep; 14(1):124. PubMed ID: 36057616
[TBL] [Abstract][Full Text] [Related]
11. Association between Cerebrospinal Fluid Biomarkers for Alzheimer's Disease, APOE Genotypes and Auditory Verbal Learning Task in Subjective Cognitive Decline, Mild Cognitive Impairment, and Alzheimer's Disease.
Mandecka M; Budziszewska M; Barczak A; Pepłońska B; Chodakowska-Żebrowska M; Filipek-Gliszczyńska A; Nesteruk M; Styczyńska M; Barcikowska M; Gabryelewicz T
J Alzheimers Dis; 2016 Jul; 54(1):157-68. PubMed ID: 27472875
[TBL] [Abstract][Full Text] [Related]
12. Factors that influence the levels of cerebrospinal fluid biomarkers in memory clinic patients.
Knapskog AB; Eldholm RS; Braekhus A; Engedal K; Saltvedt I
BMC Geriatr; 2017 Sep; 17(1):210. PubMed ID: 28893185
[TBL] [Abstract][Full Text] [Related]
13. Alzheimer Disease Signature Neurodegeneration and APOE Genotype in Mild Cognitive Impairment With Suspected Non-Alzheimer Disease Pathophysiology.
Schreiber S; Schreiber F; Lockhart SN; Horng A; Bejanin A; Landau SM; Jagust WJ;
JAMA Neurol; 2017 Jun; 74(6):650-659. PubMed ID: 28319241
[TBL] [Abstract][Full Text] [Related]
14. Age-specific and sex-specific prevalence of cerebral β-amyloidosis, tauopathy, and neurodegeneration in cognitively unimpaired individuals aged 50-95 years: a cross-sectional study.
Jack CR; Wiste HJ; Weigand SD; Therneau TM; Knopman DS; Lowe V; Vemuri P; Mielke MM; Roberts RO; Machulda MM; Senjem ML; Gunter JL; Rocca WA; Petersen RC
Lancet Neurol; 2017 Jun; 16(6):435-444. PubMed ID: 28456479
[TBL] [Abstract][Full Text] [Related]
15. Amyloid is linked to cognitive decline in patients with Parkinson disease without dementia.
Gomperts SN; Locascio JJ; Rentz D; Santarlasci A; Marquie M; Johnson KA; Growdon JH
Neurology; 2013 Jan; 80(1):85-91. PubMed ID: 23243071
[TBL] [Abstract][Full Text] [Related]
16. Design and first baseline data of the DZNE multicenter observational study on predementia Alzheimer's disease (DELCODE).
Jessen F; Spottke A; Boecker H; Brosseron F; Buerger K; Catak C; Fliessbach K; Franke C; Fuentes M; Heneka MT; Janowitz D; Kilimann I; Laske C; Menne F; Nestor P; Peters O; Priller J; Pross V; Ramirez A; Schneider A; Speck O; Spruth EJ; Teipel S; Vukovich R; Westerteicher C; Wiltfang J; Wolfsgruber S; Wagner M; Düzel E
Alzheimers Res Ther; 2018 Feb; 10(1):15. PubMed ID: 29415768
[TBL] [Abstract][Full Text] [Related]
17. Cognitive and neuroimaging features and brain β-amyloidosis in individuals at risk of Alzheimer's disease (INSIGHT-preAD): a longitudinal observational study.
Dubois B; Epelbaum S; Nyasse F; Bakardjian H; Gagliardi G; Uspenskaya O; Houot M; Lista S; Cacciamani F; Potier MC; Bertrand A; Lamari F; Benali H; Mangin JF; Colliot O; Genthon R; Habert MO; Hampel H;
Lancet Neurol; 2018 Apr; 17(4):335-346. PubMed ID: 29500152
[TBL] [Abstract][Full Text] [Related]
18. FDG-PET as an independent biomarker for Alzheimer's biological diagnosis: a longitudinal study.
Ou YN; Xu W; Li JQ; Guo Y; Cui M; Chen KL; Huang YY; Dong Q; Tan L; Yu JT;
Alzheimers Res Ther; 2019 Jun; 11(1):57. PubMed ID: 31253185
[TBL] [Abstract][Full Text] [Related]
19. β-Amyloid, Tau, Neurodegeneration Classification and Eligibility for Anti-amyloid Treatment in a Memory Clinic Population.
Rosenberg A; Öhlund-Wistbacka U; Hall A; Bonnard A; Hagman G; Rydén M; Thunborg C; Wiggenraad F; Sandebring-Matton A; Solomon A; Kivipelto M
Neurology; 2022 Nov; 99(19):e2102-e2113. PubMed ID: 36130840
[TBL] [Abstract][Full Text] [Related]
20. Prognostic value of imaging-based ATN profiles in a memory clinic cohort.
Peretti DE; Ribaldi F; Scheffler M; Chicherio C; Frisoni GB; Garibotto V
Eur J Nucl Med Mol Imaging; 2023 Sep; 50(11):3313-3323. PubMed ID: 37358619
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]